Revance Logo
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
ABOUTLEADERSHIPBOARDPARTNERSHIPS
SUSTAINABILITYMEDICAL EDUCATIONAL GRANTSINVESTIGATOR SPONSORED TRIALS
Company
INVESTOR RELATIONSPRESS RELEASESEVENTS + PRESENTATIONSFINANCIALS & FILINGSCORPORATE GOVERNANCE
STOCK INFORMATIONANALYST COVERAGEINVESTOR FAQSCONTACT US
Investors
OPPORTUNITIESCULTUREBENEFITS
Careers
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
Facebook logoInstagram logoTwitter logoLinkedIn logo
1222 Demonbreun St
20th Floor
Nashville, TN 37203
+1 (510) 742-3400
LoginContact Revance
Back
January 17, 2019
Revance Announces Pricing of Public Offering of Common Stock
January 15, 2019
Revance Announces Proposed Public Offering of Common Stock
January 15, 2019
Revance Announces Ground-Breaking Data Presentations at Leading International Neurotoxin Conference
January 7, 2019
Revance Highlights Recent Regulatory Progress and Provides Anticipated 2019 Milestones
December 4, 2018
Revance Announces China Market License Agreement with Fosun Pharma for RT002
December 4, 2018
Revance’s RT002 Demonstrates Unprecedented Efficacy and Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program
November 20, 2018
Revance to Participate in Upcoming Investor Conferences
November 7, 2018
Revance to Participate in the Credit Suisse Healthcare Conference
November 1, 2018
Revance Releases Third Quarter 2018 Results
October 18, 2018
Revance Therapeutics to Release Third Quarter 2018 Financial Results on Thursday, November 1, 2018
Displaying 141 - 150 of 296